Cite

    Ohm, L. et al. (n.d.). Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib. Leukemia & lymphoma. 56 (5), pp. 1385-1391. [Online].